This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Sirtuin 6 (SIRT6)

Patient tissue and mouse studies suggest activating SIRT6 could help modulate tumor metabolism to treat cancer. In cancer patient data from The Cancer Genome Atlas, SIRT6 was deleted in 20% of all cancers. In a genetic mouse model of colorectal adenomatosis, Sirt6 deletion in the intestines increased the frequency, size and invasiveness of adenomas compared with no deletion. In that model, the Sirt6 deletion also increased glucose uptake and glycolytic gene expression in tumors. Next steps include screening studies to identify molecules that activate SIRT6.

SciBX 6(1); doi:10.1038/scibx.2013.5
Published online Jan. 10, 2013

Unpatented; licensing status not applicable

Sebastián, C. et al. Cell; published online Dec. 7, 2012;
doi:10.1016/j.cell.2012.10.047
Contact: Raul Mostoslavsky, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.
e-mail:
rmostoslavsky@mgh.harvard.edu

Contact: David B. Lombard, University of Michigan, Ann Arbor, Mich.
e-mail:
davidlom@umich.edu